This poster presents the first comprehensive analysis of actionable driver mutations in Slovenian non-squamous NSCLC patients tested through a unified national NGS program. National reflex and routine NGS testing initiated in 2022 enabled analysis of more than 2,500 patients in the Slovenian cohort and a clinically detailed subgroup diagnosed at University Clinic Golnik, the UCG cohort. The study reports driver mutation frequencies across the full cohort and compares their distribution between early and late stage disease within the UCG group. Results show similar frequencies across stages, suggesting that key oncogenic alterations arise early and supporting further evaluation of biomarker guided targeted therapies for early stage NSCLC.

Published for CELCC 2025.